Measles in bone marrow transplant recipients during an outbreak in São Paulo, Brazil.
In 1997, a measles outbreak was identified in São Paulo. Between February and December, 20 185 cases were confirmed. From April to July 1997, a seroepidemiologic survey was conducted to identify the recipients of bone marrow (BM) transplants who were susceptible to measles and the occurrence of measles in this population. A total of 156 patients were screened by enzyme immunoassay (EIA). Patients with IgG titers more than 100 mIU/mL were considered immune. Measles reimmunization records were also reviewed. Thirty-two vaccinated patients underwent serologic evaluation. Six of 22 patients (27.3%) within 3 years after vaccination lost measles immunity, in contrast to 7 of 10 patients (70%) vaccinated longer than 3 years previously (P =.049). Among the 122 nonvaccinated patients, 41 (33.6%) were susceptible to measles: 4 of 47 patients (8.5%) within the first year after BM transplantation (BMT), and 37 of the 75 patients (49.3%) after the first year after BMT (P <.001). Eight recipients acquired measles, confirmed by serology (EIA). High-avidity IgG antibodies were observed in the acute phase of measles, suggesting a secondary immune response. Measles interstitial pneumonia was observed in one patient. Seven patients had mild symptoms. Exanthema was present in all patients. All but one patient had fever and nonproductive cough. Koplik spots could be observed in 5 patients. Measles can be mild in BM transplant recipients. Exanthema is frequently present but not often typical. Immunity to measles decreases after day +365 after BMT. Additional studies are needed to evaluate the safety of measles vaccine after the first year of BMT, mostly during outbreaks.
Machado
Clarisse M
CM
Virology Laboratory, Instituto de Medicina Tropical de São Paulo, University of São Paulo Medical School, SP, Brazil. clarimm@usp.br
Gonçalves
Flávio B
FB
Pannuti
Cláudio S
CS
Dulley
Frederico L
FL
de Souza
Vanda A U F
VA
D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D001938:Brazil / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D004196:Disease Outbreaks; D004198:Disease Susceptibility; D018562:Disease Transmission, Infectious; D005076:Exanthema / Q000821:virology; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D008457:Measles / Q000453:epidemiology* / Q000276:immunology / Q000635:transmission*; D008458:Measles Vaccine; D008875:Middle Aged; D018103:Morbillivirus / Q000276:immunology
D000914:Antibodies, Viral; D007074:Immunoglobulin G; D008458:Measles Vaccine